



Microwave-assisted synthesis of pyrido[4,3-d]pyrimidine derivatives and their biological evaluation

W.A.Gad*, H.D.Al-Harbi

Department of Chemistry, Faculty of Science, Taibah University, (SAUDI ARABIA)

E-mail: wafaagad@gmail.com

ABSTRACT

In the present study, we report the important role of solvent-free conditions coupled with microwave activation and their advantages in heterocyclic synthesis. This eco-friendly approach, which was found application in facile organic synthesis, is applied to the rapid assembly of heteroatom organic compounds via cyclocondensation reactions. Combinatorial heterocyclic synthesis under solvent-free conditions is described having allowed to build a library of such heterocyclic compounds of pharmacological interest. Some of the discussed compounds show *in vitro* antimicrobial activity against *Mycobacterium tuberculosis* H37Rv (MTB) compared with some standard drugs. © 2014 Trade Science Inc. - INDIA

KEYWORDS

Pyridopyrimidines;
Microwave irradiation;
Multicomponent reaction;
Solvent-free synthesis;
Green chemistry;
Antibacterial activity.

INTRODUCTION

Since the appearance of the reference first papers^[1] on the application of microwave irradiation in organic syntheses, the field has seen a steady growth to point where a variety of transformations are now possible with microwave heating^[2,15-21]. Carrying out the reactions using microwave heating, as opposed to conventional heating, has the major advantage of shorter reaction times because of the rapid heating. Consequently, reactions exhibit cleaner products made more facile work-up procedures.

Pyridopyrimidines are biologically interesting molecules that have established utility in the pharmaceutical and the agrochemical industries. Compounds with these ring systems have diverse pharmacological activity such as antitumor^[22,23], cardioprotective^[24,25], hepatoprotective^[24], antihypertensive^[24], antibronchitic^[26], antifungal^[27], antibacterial^[28] and antifolate^[29]. Therefore these fused

heterocycles have been extensively investigated and their synthetic preparations are well documented^[30-32]. As a result, a number of reports appeared in literature; however they usually require forcing conditions^[33], long reaction times^[34,35] and complex synthetic pathways^[29]. So new routes for the synthesis of these molecules have attracted a considerable attention as a rapid entry for the formation of these heterocycles^[36,37].

On this account, our target is to perform a facile and efficient one-pot, four-component, green synthesis of pyridopyrimidines via microwave heating and to evaluate the bioactivity of the prepared compounds.

RESULTS AND DISCUSSION


Chemistry

In the present study, we are going to synthesize a series of polysubstituted [4,3-d] pyridopyrimidines via one-pot multicomponent reaction of N-substituted

piperidones ((1) and (2)) with heterocyclic aldehydes ((3),(4) and (5)) and compounds containing amide moiety, namely, urea, thiourea, semicarbazide and thiosemicarbazide under microwave irradiation in absence of solvent. The structure of the studied compounds is established on the basis of elemental analysis and spectral data. The resulting products, the pyrido[4,3-d] pyrimidine-2- ones ((10),(12),(14),(16),(18) and (20)), and the pyrido[4,3-d] pyrimidine-2- thiones ((11),(13),(15),(17),(19) and (21)) are obtained in one-pot reaction on irradiating a mixture of compounds ((1) and (2)), heterocyclic aldehydes((3),(4) and (5)), and

urea, semicarbazide, thiourea, and thiosemicarbazide, respectively, in presence of solid sodium ethoxide as a catalyst, with MW irradiation at the ambient temperature.

On irradiating N- substituted piperidones ((1) and (2)), thiophene-3- carboxyaldehyde (3) and urea (6), thiourea (7), semicarbazide (8), and thiosemicarbazide (9) with MW irradiation for few minutes under free-solvent condition and in presence of sodium ethoxide as a catalyst affords the corresponding pyrido [4,3-d] pyrimidine derivatives (10_{a,b}-13_{a,b}) (examined by TLC),respectively (Scheme 1).



Scheme 1

Using similar conditions (MW / NaOEt and in absence of solvent) N-substituted piperidones ((1) and (2)) react with 5-chloro-3-furaldehyde (3) and urea (6) to give pyrido[4,3-d] pyrimidin-2- ones (14_{a,b}), respectively. Replacement of urea by thiourea(7), semicarbazide (8) and thiosemicarbazide (9) affords the corresponding pyridopyrimidine- 2- thiones (15_{a,b}) and the amino derivatives of pyridopyrimidine (16_{a,b},17_{a,b}), respectively (Scheme 2).

Similarly, pyridopyrimidine-ones (18_{a,b}), pyridopyrimidine-thiones (19_{a,b}) and 2-aminopyridopyrimidine derivatives (20_{a,b},21_{a,b}) are produced by the reaction of N-substituted piperidones ((1) and (2)) with pyridine-4-aldehyde (5), urea (6), thio-

urea (7), semicarbazide (8) and thiosemicarbazide (9), respectively (Scheme 3)


The reaction of N- substituted piperidones with heterocyclic aldehydes and compounds containing amide moiety is believed to proceed via the cyclization of the isomeric intermediate (22) to afford the desired products (10-21) (Scheme 4).

The elemental analyses and spectral data for the synthesized compounds are in accordance with the assigned structures (10-21).


Biological screening

In vitro antimicrobial screening of the synthesized compounds (10-21) were evaluated against Mycobacterium tuberculosis H37Rv (MTB). Activities of the

Full Paper



Scheme 2




Scheme 3

compounds and the minimum inhibitory concentration (MIC) of the tested compounds required to inhibit 99% of bacterial growth, were evaluated by agar diffusion method. Compounds (14_b), (15_b), (16_a), (16_b) and (17_b),

exhibited significant activity against (MTB) as compared with the reference drugs.

From the results obtained we can conclude that :

1) The N- benzyl pyridopyrimidines show better ac-



Scheme 4

TABLE 1 : MIC (μM) values of pyridopyrimidines (10-21) against MTB

Tested samples	MIC (μM)	Tested samples	MIC (μM)	Tested samples	MIC (μM)
10 _a	30.2	14 _a	55.9	18 _a	14.6
10 _b	48.2	14 _b	5.1	18 _b	21.6
11 _a	28.5	15 _a	50.3	19 _a	11.4
11 _b	48.7	15 _b	3	19 _b	20.1
12 _a	69.6	16 _a	5.1	20 _a	21.8
12 _b	51.7	16 _b	2.2	20 _b	39.4
13 _a	64.3	17 _a	51	21 _a	60
13 _b	42.1	17 _b	6	21 _b	57

TABLE 2 : MIC (μM) values of standard drugs

Standard reference	MIC (μM)	Standard reference	MIC (μM)
Ethambutol	7.6	Isoniazid	0.4
Ciprofloxacin	4.7	Rifampicin	0.1

tivity than their N- methyl analogs.

- 2) The presence of heterocyclic ring enhanced activity.

EXPERIMENTAL SECTION

Melting points were determined on open glass capillaries using an electrothermal IA 9000 digital melting point apparatus and are uncorrected. IR spectra are recoded (KBr) on Pye Unicam SP-1000 instrument spectrophotometer. ^1H NMR spectra are obtained on a Varian Mercury VXR -300 MHz spectrometer (CDCl_3) using tetramethylsilane (TMS) as an internal reference. Chemical shifts are expressed as δ (ppm).

Mass spectra are recorded on an MS 30 or MS 9 (AEI) mass spectrometer operating at 70 e V. The elemental analyses are formed at Micro Analytical center at Cairo University and the Micro Analytical unit at the National Research Center. Follow up the reactions and checking the purity of the compounds are made by TLC on silica gel – pre-coated aluminum sheets (Type 60 F 254, Merck, Darmstadt, Germany), and the spots are detected by exposure to UV lamp at λ_{365} nm for few seconds. The antimicrobial activity against Mycobacterium tuberculosis is evaluated by Micro analytical center, Microbiology Department, Cairo University. Microwave reactions are carried out in domestic 1000W microwave oven. All the chemicals purchased from Sigma-Aldrich company, and are used as received without further purification.

Synthesis of N - substituted pyridopyrimidine - 2-ones (10_{a,b}), (14_{a,b}) and (18_{a,b})

A mixture of N- substituted -4- piperidone, namely, N-methyl and N- benzyl -4-piperidone (1mmol), heterocyclic aldehyde, namely, 4-pyridine carboxaldehyde, 3-thiophene carboxaldehyde and 5-chloro-2- furan carboxaldehyde (2mmol), urea (0.06, 1mmol) and sodium ethoxide (2.04g, 3mmol) are subjected to microwave irradiation for about $\frac{1}{2}$ -3 min. After completion of the reaction as evident from TLC, water (50 ml) is added to the mixture and the product is filtered off and dried. The crude product is crystallized from the proper solvent.

8- (3-Thienylmethylene) -4- (3- thienyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido [4,3-d] pyrimidine

Full Paper

– 2- one (10_a)

Yield(87.76%); mp180-183°C(n-hexane); IR(KBr, ν cm⁻¹) : 3373, 3338 (NH), 1657 (C=O); ¹H NMR (CDCl₃) δ : 7.92 - 7.88 (2s, 2H, thiophene -H), 7.43-7.28 (2d, 2H, thiophene - H), 7.25 – 6.93 (2d, 2H, thiophene - H), 7.79 (s, 1H, NH), 7.85 (s, 1H, NH), 6.67 (s, 1H, -CH=), 5.06 (s, 1H, pyrimidine -H), 3.22-3.26(2d, 4H, 2CH₂, pyridine -H), 2.80 (s, 3H, N-Me); MS, m/z (%) : 343 [M⁺] (27), 260 [M⁺ - C₄H₃S] (65), 177 [260 - C₄H₃S] (13), 162 [177 - CH₃] (100); Anal. Calcd% for C₁₇H₁₇N₃O S₂ 343 (found) C 59.48 (59.45); H 4.96 (4.92); N 12.24 (12.20); S 18.66 (18.61).

8-(5-Chloro-2-furylmethylene)-4-(5-chloro-2-furyl)-6-methyl-3,4,5,6,7,8-hexahydropyrido[4,3-d] pyrimidine- 2-one (14_a)

Yield (76%); mp 172-175 °C (n-hexane); IR (KBr, ν cm⁻¹) : 3373, 3338 (NH), 1685 (C=O); ¹H NMR (CDCl₃) δ : 7.85 (s, 1H, NH), 7.79 (s, 1H, NH), 6.88 – 6.33 (4d, 4H, furan - H), 6.82 (s, 1H, -CH=), 5.18 (s, 1H, pyrimidine -H), 3.28-3.25 (2d, 4H, 2CH₂, pyridine -H), 2.35 (s, 3H, N-Me); MS, m/z (%) : 380 [M⁺] (56), 278.5 [M⁺ - C₄H₂OC] (100), 177[278.5 - C₄H₂OC] (45), 162 [177 - CH₃] (18); Anal. Calcd% for C₁₇H₁₅N₃O₃Cl₂ 380 (found) C 53.68 (53.61); H 3.95 (3.95); N 11.05 (10.9); Cl 18.68 (18.55).

8- (4-Pyridinylmethylene) -4- (4- pyridinyl)- 6-methyl- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (18_a)

Yield(89%); mp178-180°C (ethanol); IR (KBr, ν cm⁻¹) : 3444, 3140 (NH) and 1665 (C=O); ¹H NMR (CDCl₃) δ : 8.7 – 7.2 (4d, 8H, pyridine-H), 7.9 (s, 1H, NH), 7.8 (s, 1H, NH), 7.15 (s, 1H, -CH=), 5.3 (s, 1H, pyrimidine -H), 3.25-3.21 (2d, 4H, 2CH₂, pyridine -H), 2.43 (s, 3H, N-Me); MS, m/z (%) : 333 [M⁺] (37), 255 [M⁺ - C₅H₄N] (100), 177 [255 - C₅H₄N] (31), 162[177 - CH₃] (22). Anal. Calcd% for C₁₉H₁₉N₅O 333 (found) C 68.39(68.47); H 5.70(5.71); N 21.02(21).

6-Benzyl -8-(3-thienylmethylene) -4- (3- thienyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (10_b)

Yield(91%); mp120-122° C(ethanol); IR (KBr, ν cm⁻¹) : 3420, 3380 (NH), 1710 (C=O); ¹H NMR

(CDCl₃) δ : 7.9 - 7.7(2s, 2H, thiophene - H), 7.63 - 7.59 (2d, 2H, thiophene - H), 7 - 6.9 (2d, 2H, thiophene - H), 7.89 (s, 1H, NH), 7.4 (s, 1H, NH), 7.1-7.1 (m, 5H, aromatic-H), 6.82 (s, 1H, -CH=), 5.1 (s, 1H, pyrimidine -H), 3.72 (s, 2H, CH₂Ph), 2.8-2.1 (2d, 4H, 2CH₂, pyridine -H); MS, m/z (%) : 419 [M⁺] (57), 336 [M⁺ - C₄H₃S] (100), 253 [336 - C₄H₃S] (36), 176[253 - C₆H₅] (81), 162[176 - CH₂] (28); Anal. Calcd% for C₂₃H₂₁N₃O S₂ 419 (found) C 65.87 (65.8); H 5.01 (4.9); N 10.02 (10); S 15.27 (14.88).

6-Benzyl -8-(5-Chloro-2-furylmethylene) -4- (5-chloro-2-furyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (14_b)

Yield (81%); mp 104-106°C (n-hexane); IR (KBr, ν cm⁻¹) : 3410, 3370 (NH), 1720 (C=O); ¹H NMR (CDCl₃) δ : 7.9(s, 1H, NH), 7.8 (s, 1H, NH), 7.1-6.9(m, 5H, aromatic-H) 6.89 – 6.32 (4d, 4H, furan - H), 6.62 (s, 1H, -CH=), 5.1 (s, 1H, pyrimidine -H), 3.26-3.23 (2d, 4H, 2CH₂, pyridine -H), 3.69 (s, 2H, CH₂Ph) MS, m/z (%) : 456 [M⁺] (65), 354.5 [M⁺ - C₄H₂OC] (100), 253[354.5 - C₄H₂OC] (37), 176 [253 - C₆H₅] (33), 162[176 - CH₂] (29); Anal. Calcd% for C₂₃H₁₉N₃O₃Cl₂ 456 (found) C 60.53(60.49); H 4.17 (4.13); N 9.21 (9.18); Cl 15.57 (15.56).

6-Benzyl -8-(4-pyridinylmethylene) -4- (4-pyridinyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (18_b)

Yield(73%); mp131-133°C(ethanol); IR (KBr, ν cm⁻¹) : 3420, 3380 (NH), 1710 (C=O); ¹H NMR (CDCl₃) δ : 8.5 – 7.4 (4d, 8H, pyridine-H), 7.9 (s, 1H, NH), 7.8 (s, 1H, NH), 7.1 (s, 1H, -CH=), 5.3 (s, 1H, pyrimidine -H), 3.28-3.22 (2d, 4H, 2CH₂, pyridine -H). 2.23 (s, 3H, N-Me); MS, m/z (%) : 409 [M⁺] (33), 331 [M⁺ - C₅H₄N] (100), 253 [331 - C₅H₄N] (62), 176[253 - C₆H₅] (70), 162 [176 - CH₂] (58); Anal. Calcd% for C₂₅H₂₃N₅O 409 (found) C 73.35 (73.32); H 5.62 (5.6); N 17.11 (17.1).

Synthesis of N - substituted pyridopyrimidine -2-thiones (11_{a,b}), (15_{a,b}) and (19_{a,b})

A mixture of N- substituted -4- piperidone, namely, N-methyl and N- benzyl -4-piperidone (1mmol), heterocyclic aldehyde, namely, 3-thiophenecarboxaldehyde, 5-chloro-2-furan carboxaldehyde and 4-pyridine carboxaldehyde

(2mmol), thiourea (0.76, 1mmol) and sodium ethoxide (2.04g, 3mmol) are subjected to microwave irradiation for about 1/2-3 min. After completion of the reaction as evident from TLC, water (50 ml) is added to the mixture and the product is filtered off and dried. The crude product is crystallized from the proper solvent.

8- (3-Thienylmethylene) -4- (3- thienyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (11_a)

Yield(85%); mp186-188°C (n-hexane); IR (KBr, ν cm⁻¹) : 3360, 3320 (NH); ¹H NMR (CDCl₃) δ : 7.85 – 7.80 (2s, 2H, thiophene – H), 7.40 - 7.35 (2d, 2H, thiophene – H), 7.69 – 6.87 (2d, 2H, thiophene – H), 7.79(s, 1H, NH), 7.85 (s, 1H, NH), 6.62 (s, 1H, -CH=), 5.3 (s, 1H, pyrimidine –H), 3.35-3.22 (2d, 4H, 2CH₂, pyridine –H), 2.1 (s, 3H, N-Me); MS, m/z (%) : 359 [M⁺] (39), 276 [M⁺ -C₄H₃S] (86), 193 [276 – C₄H₃S] (100), 178[193 –CH₃] (55); Anal. Calcd% for C₁₇H₁₇N₃S₃ 359 (found) C 56.82 (56.79); H 4.73(4.62); N 11.70 (11.60); S 26.74 (26.51).

8-(5-Chloro-2-furylmethylene) -4- (5-chloro-2-furyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido [4,3-d] pyrimidine - 2- thione (15_a)

Yield(71%); mp180-183°C (n-hexane); IR (KBr, ν cm⁻¹) : 3320, 3315 (NH); ¹H NMR (CDCl₃) δ : 6.90-6.31 (4d, 4H, furan – H), 7.8 (s, 1H, NH), 7.7 (s, 1H, NH), 6.65 (s, 1H, -CH=), 5.2 (s, 1H, pyrimidine –H), 3.28-3.25 (2d, 4H, 2CH₂, pyridine –H), 2.32 (s, 3H, N-Me); MS, m/z (%) : 396 [M⁺] (46), 294 [M⁺ - C₄H₂OCl] (54), 193 [294 – C₄H₂OCl] (100), 178[193 –CH₃] (33); Anal. Calcd% for C₁₇H₁₅N₃O₂ SCl₂ 396 (found) C 51.52(51); H 3.79(3.62); N 10.61(10.60); S 8.08 (7.93), Cl 17.93 (17.8).

8- (4-Pyridinylmethylene) -4- (4- pyridinyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (19_a)

Yield(73%); mp166-169°C (ethanol); IR (KBr, ν cm⁻¹) : 3440, 3390 (NH); ¹H NMR (CDCl₃) δ : 8.7 – 7.49 (4d, 8H, pyridine-H), 7.8 (s, 1H, NH), 7.62 (s, 1H, NH), 7.22 (s, 1H, -CH=), 5.38 (s, 1H, pyrimidine –H), 2.15 (s, 3H, N-Me), 3.25-3.22 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : MS, m/z (%) : 349 [M⁺] (79%), 271 [M⁺ -C₅H₄N] (83%), 193 [271- C₅H₄N] (100%), 178[193 –CH₃] (32%); Anal. Calcd% for

C₁₉H₁₉N₅S 349 (found) C 65.33 (65.15); H 5.44 (5.4) ; N 20.05 (19.7); S 9.16 (9.1).

6-Benzyl -8-(3-thienylmethylene) -4- (3- thienyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (11_b)

Yield(80%); mp148-149°C (n-hexane); IR (KBr, ν cm⁻¹) : 3410, 3330 (NH); ¹H NMR (CDCl₃) δ : 7.90 – 7.86 (2s, 2H, thiophene – H), 7.48 - 7.36 (2d, 2H, thiophene – H), 7.26 – 6.90 (2d, 2H, thiophene – H), 7.60 (s, 1H, NH), 7.55 (s, 1H, NH), 6.7 (s, 1H, -CH=), 5.34 (s, 1H, pyrimidine –H), 3.54 (s, 2H, CH₂Ph), 3.30-3.22 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : 435 [M⁺] (41), 352 [M⁺ -C₄H₃S] (64%), 269 [352 – C₄H₃S] (31%), 192[269 –C₆H₅] (26%), 178[192-CH₂] (100%); Anal. Calcd% for C₂₃H₂₁N₃S₃ 435 (found) C 63.45 (63.39); H 4.83 (4.79); N 9.66 (9.6); S 22.07 (22).

6-Benzyl -8-(5-chloro-2-furylmethylene) -4- (5-chloro-2-furyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (15_b)

Yield(69%); mp120-123°C (n-hexane); IR (KBr, ν cm⁻¹) : 3410, 3370 (NH); ¹H NMR (CDCl₃) δ : 6.87-6.30 (4d, 4H furan-H), 7.25 (s, H, NH), 7.1 (s, 1H, NH), 7.6-7.3 (m, 5H, aromatic-H), 6.62 (s, 1H, -CH=), 5.20(s, 1H, pyrimidine –H), 3.67 (s, 2H, CH₂Ph), 3.22-3.18 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) 472 [M⁺] (35%), 370.5 [M⁺ -C₄H₂OCl] (100%), 269 [370.5 - C₄H₂OCl] (42%), 192 [269 –C₆H₅] (57%), 178 [192-CH₂] (39%); Anal. Calcd% for C₂₃H₁₉N₃O₂ SCl₂ 472 (found) C 58.47 (58.43) ; H 4.03 (4) ; N 8.90 (8.3); S 6.78 (6.57), Cl 15.04 (15).

6-Benzyl -8-(4-pyridinylmethylene) -4- (4- pyridinyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (19_b)

Yield(78%); mp164-166°C (ethanol); IR (KBr, ν cm⁻¹) : 3425, 3360 (NH); ¹H NMR (CDCl₃) δ 8.60 – 7.19 (4d, 8H, pyridine – H), 7.8 (s, 1H, NH), 7.6 (s, 1H, NH), 7.4-7.2 (m, 5H, aromatic-H), 6.65 (s, 1H, -CH=), 5.2 (s, 1H, pyrimidine –H), 3.72 (s, 2H, CH₂Ph), 3.26-3.20 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : MS, m/z (%) : 425 [M⁺] (34%), 347 [M⁺ -C₅H₄N] (100%), 269 [347 – C₅H₄N] (44%), 192[269 –C₆H₅] (52%), 178[192- CH₂] (33%); Anal. Calcd% for C₂₅H₂₃N₅S 425 (found) C 70.59(70.51); H 5.41(5.39);

Full Paper

N 16.47(16.42); S 7.53 (7.5).

Synthesis of 3- Amino- N - substituted pyridopyrimidine -2- ones (12_{a,b}), (16_{a,b}) and (20_{a,b})

A mixture of N- substituted -4- piperidone, namely, N-methyl and N- benzyl -4-piperidone (1mmol), heterocyclic aldehyde, namely, 4-pyridine carboxaldehyde, 3- thiophenecarboxaldehyde and 3- furan carboxaldehyde (2mmol), semicarbazide (0.75, 1mmol) and sodium ethoxide (2.04g, 3mmol) are subjected to microwave irradiation for about ½-3 min. After completion of the reaction as evident from TLC, water (50 ml) is added to the mixture and the product is filtered off and dried. The crude product is crystallized from the proper solvent.

3-Amino-8- (3-thienylmethylene) -4- (3- thienyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (12_a)

Yield(86%); mp158-160°C(n-hexane); IR (KBr, ν cm⁻¹) : 3330(NH), 3345-3340 (NH₂), 1657(C=O); ¹H NMR (CDCl₃) δ : 12.9 (s, 2H, NH₂), 7.94-7.88 (2s, 2H, thiophene – H), 7.48- 7.30 (2d, 2H, thiophene – H), 7.26 – 6.92 (2d, 2H, thiophene – H), 7.79 (s, 1H, NH), 7.21 (s, 1H, - CH=), 5.2 (s, 1H, pyrimidine –H), 3.34-3.9 (2d, 4H, 2CH₂, pyridine –H), 2.27 (s, 3H, N-Me); MS, m/z (%) : 358 [M⁺] (29%), 275 [M⁺ - C₄H₃S] (53%), 192 [275 – C₄H₃S] (77%), 177[192 – CH₃] (40%), 161[177-NH₂] (100%); Anal. Calcd% for C₁₇H₁₈N₄O₂S 358 (found) C 56.98(56.82); H 5.03 (5.02); N 15.64(15.60); S 17.88 (17.80).

3-Amino-8-(5-chloro-2-furylmethylene) -4- (5-chloro-2- furyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido [4,3-d] pyrimidine - 2- one (16_a)

Yield(80%); mp172-175°C (n-hexane); IR (KBr, ν cm⁻¹) : 3373 (NH), 3350-3325 (NH₂), 1685 (C=O); ¹H NMR (CDCl₃) δ : 12.77 (s, 2H, NH₂), 6.88-6.31 (d, 4H, furan – H), 7.45 (s, 1H, NH), 6.8 (s, 1H, - CH=), 5.3 (s, 1H, pyrimidine –H), 2.23 (s, 3H, N-Me), 3.28-3.20 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : 395 [M⁺] (77%), 293.5 [M⁺ - C₄H₂OCl] (66%), 192[293.5- C₄H₂OCl] (100%), 177 [192-CH₃] (35%), 161[177-NH₂] (56%); Anal. Calcd% for C₁₇H₁₆N₄O₃Cl₂ 395 (found) C 51.65(51.62); H 4.05 (4); N 14.18(14.16); S 17.97 (17.90).

3-Amino- 8- (4-pyridinylmethylene) -4- (4-

pyridinyl)- 6- methyl- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (20_a)

Yield(69%); mp158-160°C (ethanol); IR (KBr, ν cm⁻¹) : 3360 (NH), 3350-3325 (NH₂), 1672 (C=O); ¹H NMR (CDCl₃) δ : 10.90 (s, 2H, NH₂), 8.70 – 7.20 (4d, 8H, pyridine-H), 6.89 (s, 1H, NH), 6.77 (s, 1H, - CH=), 5.30 (s, 1H, pyrimidine –H), 3.29-3.20 (2d, 4H, 2CH₂, pyridine –H), 2.1 (s, 3H, N-Me); MS, m/z (%) : 348 [M⁺] (100%), 270 [M⁺ - C₅H₄N] (82%), 192 [255 - C₅H₄N] (58%), 177[192 – CH₃] (71%), 161[177-NH₂] (28%); Anal. Calcd% for C₁₉H₂₀N₆O 348 (found) C 65.52 (65.49); H 5.75 (5.71); N 24.14 (24).

3-Amino-6-benzyl -8-(3-thienylmethylene) -4- (3-thienyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (12_b)

Yield(75%); mp127-130°C (ethanol); IR (KBr, ν cm⁻¹) : 3388 (NH), 3350-3325 (NH₂), 1662 (C=O); ¹H NMR (CDCl₃) δ : 12.2 (s, 2H, NH₂), 7.96-7.89 (2s, 2H, thiophene – H), 7.41 - 7.28 (2d, 2H, thiophene – H), 7.3 – 6.9 (2d, 2H, thiophene – H), 7.7 (s, 1H, NH), 7.4-7.1 (m, 5H, aromatic-H), 6.9 (s, 1H, - CH=), 5.38 (s, 1H, pyrimidine –H), 3.7 (s, 2H, CH₂Ph), 3.35-3.20 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : 434 [M⁺] (35%), 351 [M⁺ - C₄H₃S] (100%), 268 [351 – C₄H₃S] (65%), 191[268 – C₆H₅] (28%), 177[191- CH₂] (30%), 161 [177 – NH₂] (32%). Anal. Calcd% for C₂₃H₂₂N₄O S₂ 434 (found) C 63.59 (63.49); H 5.07 (5.01); N 12.90 (12.8); S 14.75 (14.6).

3-Amino-6-benzyl -8-(5-chloro-2-furylmethylene) -4- (5-chloro-2-furyl)- 3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- one (16_b)

Yield(69%); mp142-144°C (n-hexane); IR (KBr, ν cm⁻¹) : 3410 (NH), 3390-3380 (NH₂), 1690 (C=O); ¹H NMR (CDCl₃) δ : 11.9 (s, 2H, NH₂), 6.96 – 6.33 (4d, 4H furan-H), 7.5 (s, H, NH), 7.1-6.9 (m, 5H, aromatic-H), 6.65 (s, 1H, - CH=), 5.5 (s, 1H, pyrimidine –H), 3.65-3. (s, 2H, CH₂Ph), 3.35-3.20 (2 d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : 471 [M⁺] (36%), 369.5 [M⁺ - C₄H₂OCl] (61%), 268 [369.5 - C₄H₂OCl] (100%), 191 [268 – C₆H₅] (80%), 177[191- CH₂] (30%), 161 [177- NH₂] (18%); Anal. Calcd% for C₂₃H₂₀N₄O₃Cl₂ 471 (found) C 58.60 (58.52); H 4.25 (4.23); N 11.89 (11.75); Cl 15.07 (15.06).

3-Amino-6-benzyl-8-(4-pyridinylmethylene)-4-(4-pyridinyl)-3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidine-2-one (20_b)

Yield(83%); mp177-179°C (n-hexane); IR (KBr, ν cm⁻¹): 3360 (NH), 3350-3310 (NH₂), 1690 (C=O); ¹H NMR (CDCl₃) δ : 12 (s, 2H, NH₂), 8.74 – 7.30 (4d, 8H, pyridine – H), 7.7(s, 1H, NH), 7.3-7.1 (m, 5H, aromatic-H), 6.62 (s, 1H, -CH=), 5.43 (s, 1H, pyrimidine –H), 3.3 (s, 2H, CH₂Ph), 3.29-3.22 (2 d, 4H, 2CH₂, pyridine –H); MS, m/z (%): 424 [M⁺] (47%), 346 [M⁺ - C₅H₄N] (100%), 268 [346 – C₅H₄N] (53%), 191[268 – C₆H₅] (23%), 177[191 – CH₂] (55%), 161[177 – NH₂] (31%); Anal. Calcd% for C₂₅H₂₄N₆O 424 (found) C 70.75 (70.63); H 5.66 (5.61); N 19.81 (19.7).

Synthesis of 3-Amino-N - substituted pyridopyrimidine -2- thiones (13_{a,b}), (17_{a,b}) and (21_{a,b})

A mixture of N- substituted -4- piperidone, namely, N-methyl and N- benzyl -4-piperidone (1mmol), heterocyclic aldehyde, namely, 3-thiophenecarboxaldehyde, 5-chloro-2- furan carboxaldehyde and 4-pyridine carboxaldehyde (2mmol), thiosemicabazide (0.91, 1mmol) and sodium ethoxide (2.04g, 3mmol) are subjected to microwave irradiation for about ½-3 min. After completion of the reaction as evident from TLC, water (50 ml) is added to the mixture and the product is filtered off and dried. The crude product is crystallized from the proper solvent.

3-Amino-8-(3-thienylmethylene)-4-(3- thienyl)-6-methyl-3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (13_a)

Yield(82%); mp130-134°C (n-hexane); IR (KBr, ν cm⁻¹): 3360 (NH), 3390-3320 (NH₂); ¹H NMR (CDCl₃) δ : : 12.6 (s, 2H, NH₂), 7.92-7.87 (2s, 2H, thiophene – H), 7.40 - 7.26 (2d, 2H, thiophene – H), 7.28 – 6.94 (2d, 2H, thiophene – H), 7.8 (s, 1H, NH), 6.80 (s, 1H, -CH=), 5.48 (s, 1H, pyrimidine –H), 3.4-3.25 (2d, 4H, 2CH₂, pyridine –H), 2.25 (s, 3H, N-Me); MS, m/z (%): 374[M⁺] (19%), 291[M⁺ - C₄H₃S] (100%), 208[291 C₄H₃S] (76%), 193[208 – CH₃] (85%), 177[193 – NH₂] (47%); Anal. Calcd% for C₁₇H₁₈N₄S₃374 (found) C 54.55 (54.49); H 4.81

(4.79); N 14.97 (14.93); S 25.67 (25.6).

3-Amino-8-(5-chloro-2-furylmethylene) -4- (5-chloro-2- furyl)- 6- methyl- 3,4,5,6,7,8-hexahydropyrido [4,3-d] pyrimidine - 2- thione (17_a)

Yield(78%); mp148-150°C (n-hexane); IR (KBr, ν cm⁻¹): 3388 (NH), 3390-3325 (NH₂); ¹HNMR(CDCl₃) δ : 11.8 (s, 2H, NH₂), 6.75 – 6.36 (4 d, 4H, furan – H), 7.65 (s, 1H, NH), 6.3 (s, 1H, -CH=), 5.1 (s, 1H, pyrimidine –H), 3.25-3.22 (2 d, 4H, 2CH₂, pyridine –H), 1.91 (s, 3H, N-Me); MS, m/z (%): MS, m/z (%): 411 [M⁺] (27%), 309.5 [M⁺ - C₄H₂OCl] (55%) 208 [309.5 – C₄H₂OCl](100%), 193[208 – CH₃] (40%), 177[193 – NH₂] (62%); Anal. Calcd% for C₁₇H₁₆N₄O₂SCl₂ 411(found) C 49.64 (49.6); H 3.89(3.81); N 13.63 (13.59); S 7.79 (7.7), Cl 17.27 (17.21).

3-Amino- 8- (4-pyridinylmethylene) -4- (4-pyridinyl)- 6- methyl- 3,4,5,6,7,8-hexahydropyrido[4,3-d] pyrimidine – 2- thione (21_a)

Yield(72%); mp150-153°C (ethanol); IR (KBr, ν cm⁻¹): 3383, (NH), 3350-3325 (NH₂); ¹H NMR (CDCl₃) δ 10.90 (s, 2H, NH₂), 8.70 – 7.20 (4d, 8H, pyridine-H), 7.79 (s, 1H, NH), 6.82 (s, 1H, -CH=), 5.42 (s, 1H, pyrimidine –H), 3.30-3.26 (2d, 4H, 2CH₂, pyridine –H), 2.13 (s, 3H, N-Me); MS, m/z (%): MS, m/z (%): 364 [M⁺] (34%), 286 [M⁺ - C₅H₄N] (65%), 208 [286 - C₅H₄N] (100%), 193[208 – CH₃] (26%), 177[193 – NH₂] (21%); Anal. Calcd% for C₁₉H₂₀N₆S 364 (found) C 62.64 (61.92); H 5.49 (5.41); N 23.07 (23); S 8.79 (8.63).

3-Amino-6-Benzyl-8-(3-thienylmethylene)-4-(3-thienyl)-3,4,5,6,7,8- hexahydropyrido[4,3-d] pyrimidine – 2- thione (13_b)

Yield(82%); mp138-140°C(n-hexane); IR (KBr, ν cm⁻¹): 3420, (NH), 3350-3325 (NH₂).¹H NMR (CDCl₃) δ : 12.79 (s, 2H, NH₂), 7.90-7.88 (2s, 2H, thiophene – H), 7.44 - 7.29 (2d, 2H, thiophene – H), 7.22 – 6.78 (2d, 2H, thiophene – H), 7.7 (s, 1H, NH), 7.5-7.1 (m, 5H, aromatic-H), 6.8 (s, 1H, -CH=), 5.1 (s, 1H, pyrimidine –H), 3.7 (s, 2H, CH₂Ph), 3.35-3.24, (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%): 450 [M⁺] (86%), 367 [M⁺ - C₄H₃S] (51%), 284 [367 –

Full Paper

C₄H₃S](33%), 207[284 –C₆H₅] (100%), 193[207-CH₂] (66%), 177[193 –NH₂] (27%); Anal. Calcd% for C₂₃H₂₂N₄S₃ 450 (found) C 61.3 (61.1) ; H 4.89 (4.70) ; N 12.44 (14.40) ; S 21.33 (21.2).

3-Amino-6-benzyl-8-(5-chloro-2-furylmethylene)-4-(5-chloro-2-furyl)-3,4,5,6,7,8-hexahydropyrido[4,3-d] pyrimidine – 2- thione (17_b)

Yield(77%); mp135-137°C (n-hexane); IR (KBr, ν cm⁻¹) : 3410 (NH), 3350-3310 (NH₂); ¹H NMR(CDCl₃) δ : 12.85 (s, 2H, NH₂), 6.98 – 6.36 (4 d, 4H furan-H), 6.97 (s, H, NH), 7.4-7.1 (m, 5H, aromatic-H), 6.55 (s, 1H, -CH=), 4.45 (s, 1H, pyrimidine –H), 3.4 (s, 2H, CH₂Ph), 3.28-3.22 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : MS, m/z (%) : 487 [M⁺] (71%), 385.5 [M⁺ -C₄H₂OCl] (100%), 284 [385.5 - C₄H₂OCl] (40%), 207[284 –C₆H₅] (25%), 193[207-CH₂] (12%), 177[193 –NH₂] (33%). Anal. Calcd% for C₂₃H₂₀N₄O₂SCl₂ 487 (found) C 56.67 (56.62) ; H 4.11 (4.10); N 11.50 (11.35); S 6.57(6.51), Cl 14.58 (14.48).

3-Amino-6-benzyl-8-(4-pyridinylmethylene)-4-(4-pyridinyl)-3,4,5,6,7,8-hexahydropyrido[4,3-d] pyrimidine – 2- thione (21_b)

Yield(72%); mp166-168°C (ethanol); IR (KBr, ν cm⁻¹) : 3380, (NH), 3350-3310 (NH₂); ¹H NMR (CDCl₃) δ 12.90 (s, 2H, NH₂), 8.6 – 7.22 (4d, 8H, pyridine – H), 7.65 (s, 1H, NH), 7.59 (s, 1H, NH), 7.20-7.1 (m, 5H, aromatic-H), 6.63 (s, 1H, -CH=), 4.39 (s, 1H, pyrimidine –H), 3.37 (s, 2H, CH₂Ph), 3.26-3.2 (2d, 4H, 2CH₂, pyridine –H); MS, m/z (%) : MS, m/z (%) : 440 [M⁺] (63%), 362 [M⁺ -C₅H₄N] (100%), 284 [362 – C₅H₄N] (27%), 207[284 –C₆H₅] (65%), 193[207-CH₂] (31%), 177[193 –NH₂] (11%); Anal. Calcd% for C₂₅H₂₄N₆S 440 (found) C 68.18 (68.13); H 5.45 (5.41); N 19.09 (18.90); S 7.27 (7.13).

CONCLUSION

- A simple, efficient and benign methodology for the syntheses of pyridopyrimidinederivatives is described.
- Under microwave irradiation and free-solvent condition, heterocyclic aldehydes, N-substituted acyclic ketones, and compounds containing amide moiety, cyclized to give fused pyrimidines in good

yields.

- The biological activity of the compounds prepared in this study has been assessed in screens for anti-bacterial properties.
- The results reported in this study serve to illustrate the value of diversity oriented synthesis on heterocyclic templates in the discovery of biologically active compounds.

ACKNOWLEDGMENTS

The author thanks Taibah University for funding this research project. Thanks and gratitude refer also to King Abdul-Aziz City for Science and Technology, General Directorate of Research, Grants Programs for financial support. Thanks and gratitude are expressed to Cairo University, and National Research Center, Giza, Egypt for facilities provided during this project.

REFERENCES

- [1] C.H.Lee, M.Jiang, M.Cowart, G.Gfesser, R.Perner, K.H.Kim, Y.G.Gu, M.W.Williams, F.Michael, M.F.Jarvis, E.A.Kowaluk, A.O.Stewart, S.Shripad, S.S.Bhagwat; J.Med.Chem., **44**, 2133 (2001).
- [2] M.M.Martinez, J.M.Bartoioime-Nebreda, I.Gomez-Monterrey, R.Gonzalez-Muniz, M.T.Garcia-Lopez, S.Ballaz, A.Barber, A.Fortuno, J.D.Rio, R.Herranz; J.Med.Chem., **40**, 3402 (1997).
- [3] A.M.Thompson, D.K.Murray, W.L.Elliott, D.W.Fry, J.A.Nelson, H.D.H.Showalter, B.J.Roberts, P.W.Vincent, W.A.Denny; J.Med.Chem., **40**, 3915 (1997).
- [4] H.A.Parish, R.D.Gilliom et al.; J.Med.Chem., **25**, 98 (1982).
- [5] H.El-Subbagh, S.M.Abu-Zaid, M.A.Mahran, F.A.Badria, A.M.Al-Obaid; J.Med.Chem., **43**, 2915 (2000).
- [6] S.A.F.Rostom, G.S.Hassan, H.L.El-Subbagh; Arch.Der.Pharm., **342**, 584 (2009).
- [7] A.Gangjee, O.Aldair, S.F.Queener; J.Med.Chem., **42**, 2447- 2455 (1999).
- [8] E.M.Grivsky, S.Lee, C.W.Sigel, D.S.Duch, C.O.Nichol; J.Med.Chem., **23**, 327-329 (1980).
- [9] L.Cordeu, E.Cubedo, E.Bandres et al.; Bioorg.Med. Chem., **15**, 1659 (2007).
- [10] J.R.Piper, G.S.McCaleb, J.A.Montgomery et al.; J.Med.Chem., **29**, 1080 (1986).

- [11] A.V.Zakharov, M.Yu.Gavrilov, L.M.Demina, G.N.Novoselova, N.A.Gornova, M.Ye.Konshin, Zh.Kim-Farm; **28**, 24-26 (1994).
- [12] L.F.Kuyper, J.M.Garvey et al.; Bioorg.Med.Chem., **4**, 593 (1996).
- [13] J.M.Quintela, C.Peinador, L.Botana et al.; Bioorg.Med.Chem., **5**, 1543 (1997).
- [14] A.Rosowsky, C.E.Mota, S.F.Queener; J.Heterocycl.Chem., **32**, 335 (1995).
- [15] J.I.DeGraw, P.H.Christie, W.T.Clowell, F.M.Sirotnak; J.Med.Chem., **35**, 320-324 (1992).
- [16] S.Furuya, T.Ohtaki; Eur.Pat.Appl., Ep121, (1994), Chem.Abstr., 205-395 (1994).
- [17] D.Heber, C.Heers, U.Ravens, Pharmazie, **48**, 537-541 (1993).
- [18] Y.Sakuma, M.Hasegawa, K.Kataoka, K.Hoshina, N.Yamazaki, T.Kadota, H.Yamaguchi; PCT Int.Appl., **115**, 71646u (1991).
- [19] G.Singh, A.K.Yadav, K.Mishraa; Ind.J.Chem., **41**, 430-432 (2002).
- [20] A.Pastor, R.Alajarin et al.; Tetrahedron, **50**, 8085 (1994).
- [21] V.E.Kolla, A.B.Deyanov, F.Y.Nazmetdinov et al.; Pharm.Chem.J., **27**, 635 (1993).
- [22] P.Andrus, T.Fleck et al.; J.Neurosci.Res., **47**, 650 (1997).
- [23] A.R.Katritzky, C.W.Rees, (Eds); Comprehensive Heterocyclic Chemistry, **3**, 129-261 (1984).
- [24] G.Tamura, T.Sakaguchi, T.Kawasaki, Y.Kita; Heterocycles, **3**, 183-186 (1975).
- [25] J.Quirog, A.Hormaza, B.Insuasty, M.Nogueras, A.Sanchez; J.Heterocycl.Chem., **34**, 521-524 (1997).
- [26] K.Hirota, H.Kuki, Y.Maki; Heterocycles, **37**, 563-570 (1994).
- [27] P.Srivastava, A.S.Saxena, V.J.Ram; Synthesis, 541-544 (2000).
- [28] A.D.Broom, J.L.Shim, G.L.Anderson; J.Org.Chem., **41**, 1095-1099 (1976).
- [29] T.B.Brown, M.F.Stevens; J.Chem.Soc., Perkin Trans., **1**, 1023 (1975).
- [30] R.S.Hosmane, B.B.Lim, M.F.Summers, N.S.Hosmane; J.Org.Chem., **53**, 5309 (1988).
- [31] P.Bhuyan, R.C.Boruah, J.S.Sandhu; J.Org.Chem., **55**, 568 (1990).
- [32] M.Kajino, K.Meguro; Heterocycles, **31**, 2153 (1990).
- [33] A.M.Thompson, A.J.Bridges, D.W.Fry, A.J.Kraker, W.A.Denny; J.Heterocycl.Chem., **38**, 3780 (1995).
- [34] C.Sanmartín, M.V.Domínguez, L.Cordeu, E.Cubedo, J.García-Foncillas, M.Font, J.A.Palop; Arch.Pharm.Chem.Life Sci., **341**, 28-41 (2008).
- [35] M.Font et al.; Eu.J.Med.Chem., **46**, 3887-3899 (2011).
- [36] L.Klisiecki, E.Sucharda; Roczniki Ckm., **3**, 251 (1923).
- [37] S.Ravikanth, R.G.Venkat, D.P.Shanthan, B.Narsaiah; Synth.Comm., **34**, 4463-4469 (2004).